Entries by CAPTIS

Nektar’s NKTR-181 shown to reduce chronic pain in phase 3 trial

Published 21 March 2017 Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction […]

SalvaRx to invest in Rift Biotherapeutics

Published 21 March 2017 SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology. Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion […]

MedLumics secures EUR34.4m in series B funding

Published 21 March 2017 MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, has raised €34.4m in financing that will be used to help advance the product and clinical development of the company’s AblaView catheter, intended for the treatment of atrial fibrillation (AF) and other arrhythmias. This financing is the largest in […]

Bristol-Myers Squibb, CytomX extend cancer collaboration

PBR Staff Writer Published 21 March 2017 Bristol-Myers Squibb (BMS) is paying CytomX Therapeutics $200m upfront to add up to eight new candidates to their existing Probody therapeutics collaboration. In May 2014, both firms signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s Probody […]

A nasal spray for bulimia? Opiant enters Phase 2 trials

In 2017, the drug naloxone is almost a household name. It’s a frontline therapy for reviving individuals that have overdosed on opioids such as heroin, oxycontin, and fentanyl — an increasingly common occurrence in U.S. towns ravaged by an epidemic of opioid abuse. Opiant Pharmaceuticals has been part of that crusade with the FDA approval and widespread […]

Questions Arise Over This Bay Area Biotech CEO's Doctorate Degree and His Time at the University of Pennsylvania

March 20, 2017By Mark Terry, BioSpace.com Breaking News Staff Gabriel Otte, the chief executive officer and co-founder of Palo Alto, Calif.-based Freenome, is facing a likely minor controversy over his academic credentials. Otte left the University of Pennsylvania prior to completing his PhD program, but some of his company’s publicity materials have suggested he completed […]

Former Metamark Genetics CEO to Helm Massachusets

CAMBRIDGE, Mass.–(BUSINESS WIRE)–KEW, Inc., a privately-held precision diagnostics company located in Cambridge, MA, USA, today announced the appointment of Jerry Williamson to the position of President and Chief Executive Officer and member of the Board of Directors effective March 13, 2017. “Jerry’s leadership will accelerate the adoption of our platform by clinicians, hospitals and healthcare […]

NeoTract, Inc.???s UroLift System Featured In American Urological Association???s Urology Residents BPH/LUTS Training Program

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company’s UroLift System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH), was featured in an American Urological Association (AUA) training event that took place last week at the AUA headquarters […]

3D Systems Is Offering A Scalable 3D-Printing System For Manufacturers

3D Systems Figure 4 production platform. 3D printing is ready for large-scale manufacturing. That is, if 3D Systems has anything to say about it. On Monday, the company shipped its Figure 4 production platform, a system which the company says produces plastic parts 50 times faster than comparable 3D printing systems. The system is both […]